Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 569.58% and ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

The chip maker invested about $100 million in OpenAI's latest funding round, The Wall Street Journal reports. Tesla's cheapest model is no longer on sale in the U.S.

Stocks declined on Thursday as rising tensions in the Middle East left investors uneasy ahead of September's payrolls report.

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

"God knows what volume they're actually selling. And who knows? You're just taking it," one expert told The Post.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announced that approval has been received from an independent review board, for human pilot study #3 (the "Study"), ...

Eli Lilly (LLY) weight loss therapy tirzepatide is on track to launch across England’s National Health Service ((NHS)) as ...

Eli Lilly 's (NYSE: LLY) stock is up by more than 736% over the last five years, largely thanks to its best-selling medicines for type 2 diabetes and obesity. And while it likely has plenty of upside ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, threatening to upend the many knockoffs that became popular when ...